Vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate: The role of pre-treatment bone turnover

被引：0
|
作者：
Seibel, MJ
Barton, I
Grauer, A
机构：
[1] Univ Sydney, Sydney, NSW 2006, Australia
[2] Procter & Gamble Pharmaceut, Geneva, Switzerland
来源：
OSTEOPOROSIS INTERNATIONAL | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate
    Seibel, MJ
    Naganathan, V
    Barton, I
    Grauer, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (02) : 323 - 329
  • [2] Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women
    Reginster, JY
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (02) : 121 - 122
  • [3] Bone mass gain in osteoporotic postmenopausal women treated with risedronate, with or without HRT
    Lopes, Ceci Mendes Carvalho
    Celestino, Clice Aparecida
    Halbe, Hans Wolfgang
    Hayashida, Sylvia Asaka Yamashita
    Bagnoli, Vicente Renato
    da Fonseca, Angela Maggio
    Petti, Domingos Auricchio
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (06): : 997 - 997
  • [4] Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women
    R. P. Heaney
    T. M. Zizic
    I. Fogelman
    W. P. Olszynski
    P. Geusens
    C. Kasibhatla
    N. Alsayed
    G. Isaia
    M. W. Davie
    C. H. Chesnut III
    Osteoporosis International, 2002, 13 : 501 - 505
  • [5] Risedronate reduces the risk of first vertebral fracture in osteoporotic women
    Heaney, RP
    Zizic, TM
    Fogelman, I
    Olszynski, WP
    Geusens, P
    Kasibhatla, C
    Alsayed, N
    Isaia, G
    Davie, MW
    Chesnut, CH
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 (06) : 501 - 505
  • [6] Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover
    J. Collette
    O. Bruyère
    J. M. Kaufman
    R. Lorenc
    D. Felsenberg
    T. D. Spector
    M. Diaz- Curiel
    S. Boonen
    J.-Y. Reginster
    Osteoporosis International, 2010, 21 : 233 - 241
  • [7] Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover
    Collette, J.
    Bruyere, O.
    Kaufman, J. M.
    Lorenc, R.
    Felsenberg, D.
    Spector, T. D.
    Diaz-Curiel, M.
    Boonen, S.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (02) : 233 - 241
  • [8] Two years treatment with risedronate in osteoporotic postmenopausal women
    Bernad, M
    Peiteado, D
    Bohorquez, C
    Hernandez, A
    Garces, MV
    Mola, EM
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 453 - 453
  • [9] Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women
    Bruyere, O
    Collette, J
    Delmas, P
    Rouillon, A
    Roux, C
    Seidel, L
    Richy, F
    Reginster, JY
    MATURITAS, 2003, 44 (04) : 259 - 265
  • [10] Continuous treatment of postmenopausal osteoporotic Greek women with risedronate and its effect on bone markers
    Koulouris, I. C. H.
    Kataxaki, E.
    Antipas, G.
    Makris, A.
    Metania, E.
    Mamalis, K.
    Konstantelous, E.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S233 - S233
12345